Methotrimeprazine shortage — CA supply status & alternatives

Methotrimeprazine

—

In supply · Australia

Methoprazine

In supply · 🇦🇺 Australia · short in🇨🇦 CA

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Controlled substance
Active ingredient (INN)	Methotrimeprazine
Brand names	Methoprazine
Therapeutic category	Auto-created by Health Canada — Drug Shortages Database scraper

Marketing-authorisation holders	PHARMASCIENCE INC, PRO DOC LIMITEE

Registrations on file	5

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders5 registrations · 2 MA holders

Product	Strength	Form	Market	MA holder	Status
Pms-Methotrimeprazine	—	tablet	🇨🇦 CA	PHARMASCIENCE INC	Active
Methotrimeprazine-2	—	tablet	🇨🇦 CA	PRO DOC LIMITEE	Cancelled
Methotrimeprazine-5	—	tablet	🇨🇦 CA	PRO DOC LIMITEE	Cancelled
Methotrimeprazine-25	—	tablet	🇨🇦 CA	PRO DOC LIMITEE	Cancelled
Methotrimeprazine-50	—	tablet	🇨🇦 CA	PRO DOC LIMITEE	Cancelled

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.